BG Medicine, Inc., incorporated in 2001 and headquartered in Waltham, Massachusetts, is a clinical diagnostics company focused on the development and commercialization of biomarker-based tests for cardiovascular and metabolic diseases. The company emerged from collaborative research conducted at major academic centers, and it completed its initial public offering in 2011. Over the years, BG Medicine has built its platform around the scientific validation of novel protein biomarkers, aiming to address unmet needs in risk stratification, early detection and disease management.
BG Medicine’s primary business activities center on laboratory-developed tests that measure panels of biomarkers associated with heart failure, insulin resistance and metabolic syndrome. Its flagship Cardiometabolic Panel combines assays for proteins such as insulin, adiponectin, leptin and B-type natriuretic peptide (BNP) to help clinicians assess a patient’s risk profile and guide therapeutic decisions. The company also offers custom assay development services to pharmaceutical and biotechnology partners engaged in clinical trials, leveraging its expertise in translational proteomics.
While BG Medicine’s tests are principally performed in its CLIA-certified laboratory in Massachusetts, the company serves a broader geographic footprint through distribution agreements in Europe and Asia-Pacific. Its diagnostic products are marketed to hospital laboratories, reference labs and specialty clinics in endocrinology, cardiology and primary care. Strategic collaborations with academic medical centers and contract research organizations further extend BG Medicine’s reach into emerging markets and research-driven applications.
The leadership team at BG Medicine combines seasoned professionals in diagnostics, laboratory operations and commercial development. The company’s board is chaired by industry veteran John G. Hill, and its executive ranks include President and CEO David J. Pesola, who has over two decades of experience in bringing in vitro diagnostics to market. BG Medicine’s management emphasizes rigorous scientific validation and close engagement with healthcare providers to drive adoption of its biomarker tests and support improved patient outcomes.
AI Generated. May Contain Errors.
